Neurosense Therapeutics Ltd • NRSN

Capital at risk.

About Neurosense Therapeutics Ltd
Ticker
info
NRSN
Trading on
info
NASDAQ
ISIN
info
IL0011809592
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Alon Ben-Noon
Headquarters
info
Building B, Herzliya, undefined, Israel, 4672562
Employees
info
17
Website
info
neurosense-tx.com
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Metrics
BasicAdvanced
Market cap
info
$27.1M
P/E ratio
info
-
EPS
info
-$0.36
Dividend Yield
info
0.00%
Beta
info
1.57
Forward P/E ratio
info
0
EBIDTA
info
$-8.6M
Ex dividend date
info
-
Price & volume
Market cap
info
$27.1M
Average daily volume
info
0.4M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
12.82
Earnings
EPS
info
-$0.36
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-8.6M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.57
52-week High
info
$2.60
52-week Low
info
$0.81
50-day moving average
info
$1.17
200-day moving average
info
$1.33
Short ratio
info
1.15
Short %
info
1.07%
Management effectiveness
ROE (TTM)
info
-2,478.16%
ROA (TTM)
info
-303.90%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
29.6M
Float
info
13.8M
Insiders %
info
25.55%
Institutions %
info
1.72%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 3 analysts.

Average price target

info
$11.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.11
-$0.11
-
Q3 • 24Beat
-$0.06
-$0.15
60.00%
Q4 • 24Beat
-$0.06
-$0.15
60.00%
Q1 • 25Beat
-$0.19
-$0.23
15.56%
Q2 • 25Beat
-$0.04
-$0.06
20.55%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$-2.4M
0.00%
Q1 • 25
$-2.4M
0.00%
Q2 • 25
NaN%
-0.00%
0.00%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.7M
$2.2M
130.82%
Q1 • 25
$1.7M
$2.2M
130.82%
Q2 • 25
0.00%
0.00%
0.00%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-0M
-
$0M
$-0M
Q1 • 25
$-0M
-
$0M
$-0M
Q2 • 25
-
-
0.00%
-0.00%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Neurosense Therapeutics Ltd share?
Collapse

Neurosense Therapeutics Ltd shares are currently traded for undefined per share.

How many shares does Neurosense Therapeutics Ltd have?
Collapse

Neurosense Therapeutics Ltd currently has 29.6M shares.

Does Neurosense Therapeutics Ltd pay dividends?
Collapse

No, Neurosense Therapeutics Ltd doesn't pay dividends.

What is Neurosense Therapeutics Ltd 52 week high?
Collapse

Neurosense Therapeutics Ltd 52 week high is $2.60.

What is Neurosense Therapeutics Ltd 52 week low?
Collapse

Neurosense Therapeutics Ltd 52 week low is $0.81.

What is the 200-day moving average of Neurosense Therapeutics Ltd?
Collapse

Neurosense Therapeutics Ltd 200-day moving average is $1.33.

Who is Neurosense Therapeutics Ltd CEO?
Collapse

The CEO of Neurosense Therapeutics Ltd is Alon Ben-Noon.

How many employees Neurosense Therapeutics Ltd has?
Collapse

Neurosense Therapeutics Ltd has 17 employees.

What is the market cap of Neurosense Therapeutics Ltd?
Collapse

The market cap of Neurosense Therapeutics Ltd is $27.1M.

What is the P/E of Neurosense Therapeutics Ltd?
Collapse

The current P/E of Neurosense Therapeutics Ltd is null.

What is the EPS of Neurosense Therapeutics Ltd?
Collapse

The EPS of Neurosense Therapeutics Ltd is -$0.36.

What is the PEG Ratio of Neurosense Therapeutics Ltd?
Collapse

The PEG Ratio of Neurosense Therapeutics Ltd is null.

What do analysts say about Neurosense Therapeutics Ltd?
Collapse

According to the analysts Neurosense Therapeutics Ltd is considered a buy.